quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 30, 2026

DeepSeek's DSpark Just Made Nvidia's Most Important New Bet Harder to Close

View original at nasdaq.com
DeepSeek's DSpark Just Made Nvidia's Most Important New Bet Harder to Close Key Points Nvidia's GPU business is not in question. What is in question is the incremental hardware layer Nvidia is now trying to sell on top of it…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The AWS-Cerebras disaggregated inference solution delivers inference an order of magnitude faster than existing GPU-only solutions.

    60% confidence
  • MLA compression reduced KV cache requirements by over 90% across DeepSeek's model generations.

    60% confidence
  • The Groq 3 LPX and Vera Rubin NVL72 combination delivers up to 35 times higher inference throughput per megawatt for trillion-parameter models.

    60% confidence
  • Per-user generation speed improved 60% to 85% on DeepSeek-V4-Flash and 57% to 78% on V4-Pro over the prior baseline.

    60% confidence
  • DeepSeek-V4-Pro needs roughly 10% of the memory that V3.2 required for million-token conversations.

    60% confidence
  • Stock Advisor's total average return is 902%, a market-crushing outperformance compared to 207% for the S&P 500.

    60% confidence
  • Throughput at a fixed service level improved 51%.

    60% confidence
  • Full-year fiscal 2027 Data Center revenue consensus sits near $343 billion.

    60% confidence
  • Consensus Data Center gross margin for fiscal 2027 is projected at 76.3%, slightly below fiscal 2024 and 2025 levels.

    60% confidence
  • Confirmed more than $1 trillion in combined Blackwell and Rubin purchase orders through 2027.

    60% confidence

Data points we hold from this source

Stock Advisor · market share902 percent_total_average_return
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com